S-1/A: Iterum Therapeutics Announces Rights Offering to Raise Up to $10.3 Million

Iterum Therapeutics is launching a rights offering to raise up to $10.3 million to fund its strategic process and support the review of its New Drug Application (NDA).

Summary

• Iterum Therapeutics plc is offering non-transferable subscription rights to holders of its ordinary shares and eligible warrants to purchase units.
• The company aims to raise up to $10.3 million through this rights offering.
• Each unit consists of one ordinary share, a 1-year warrant to purchase 0.5 ordinary shares, and a 5-year warrant to purchase one ordinary share.
• The subscription price is $1.21 per whole unit.
• The rights offering commences on July 22, 2024, and expires on August 6, 2024.
• The net proceeds will be used to fund the ongoing strategic process, support the NDA review for oral sulopenem, pre-commercialization activities, and for general corporate and working capital purposes, including potential repayment of the 2025 exchangeable notes.
• Maxim Group LLC is acting as the dealer-manager for the rights offering.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the company's need for capital, ongoing losses, and the risks associated with the rights offering. However, the potential for FDA approval and strategic alternatives provide some positive aspects.

Positives

• The rights offering provides existing shareholders and eligible warrant holders the opportunity to increase their investment in the company.
• The funds raised will support the company's strategic process and the potential commercialization of oral sulopenem.
• The inclusion of warrants in the units offers potential upside to investors if the share price increases.
• The company has engaged a financial advisor to assist management and the board in evaluating strategic alternatives.

Negatives

• The subscription rights are non-transferable, limiting flexibility for shareholders.
• There is no guarantee that the company will successfully raise the full $10.3 million.
• The market value of the ordinary shares may decline during or after the rights offering.
• The company has a history of losses and may require additional funding in the future.
• The company may pursue and ultimately consummate transaction, which results in investors receiving compensation in amount that is less than the Subscription Price in this Rights Offering.

Risks

• The company may not raise sufficient capital to fund its operations.
• The subscription price may not reflect the fair value of the ordinary shares or warrants.
• Shareholders may experience dilution if they do not participate in the rights offering.
• The company has broad discretion in the use of the net proceeds.
• There is no public trading market for the 1-year warrants or the 5-year warrants.
• The company may be delisted from the Nasdaq Capital Market if it fails to comply with listing requirements.
• The company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern.

Future Outlook

The company intends to use the net proceeds from this Rights Offering, together with its existing cash, cash equivalents and short-term investments, to fund its ongoing strategic process, support the ongoing review of its NDA for oral sulopenem for the treatment of uUTIs, for pre-commercialization activities and for other general corporate and working capital purposes, which may include repayment of the 6.500% Exchangeable Senior Subordinated Notes due 2025.

Management Comments

• The board of directors determined that we should focus on a strategic process to sell, license, or otherwise dispose of our rights to sulopenem with the goal of maximizing shareholder value.

Industry Context

The company is developing sulopenem to address growing concerns related to antibacterial resistance, offering a potential alternative to widely used antibiotics like fluoroquinolones.

Comparison to Industry Standards

• Rights offerings are a common method for companies, particularly in the biotech sector, to raise capital from existing shareholders.
• The terms of the offering, including the unit price and warrant structure, are typical for companies in a similar financial position.
• Comparable companies that have recently conducted rights offerings include [hypothetical company A] and [hypothetical company B], although the specific terms vary based on individual circumstances.

Stakeholder Impact

• Shareholders will have the opportunity to participate in the rights offering and potentially increase their ownership in the company.
• Employees' jobs may be affected by the outcome of the strategic process.
• The availability of sulopenem could impact patients with urinary tract infections.
• The company's creditors, including holders of the Exchangeable Notes, may be affected by the company's ability to raise capital and repay its debts.

Next Steps

• Shareholders and eligible warrant holders must decide whether to exercise their subscription rights before the expiration date.
• The company will continue to pursue its strategic process to sell, license, or otherwise dispose of its rights to sulopenem.
• The FDA will continue its review of the NDA for oral sulopenem, with a proposed Advisory Committee meeting on September 9, 2024, and a PDUFA action date of October 25, 2024.
• The company intends to seek shareholder approval of the disapplication of statutory pre-emption rights over the Additional Shares at an Extraordinary General Meeting of Shareholders whether or not it completes this Rights Offering.

Key Dates

Keywords

rights offering, Iterum Therapeutics, sulopenem, ordinary shares, warrants, NDA, subscription rights, capital raise, strategic process, PDUFA